semaglutide news oct 26 2025 The NHS will soon offer the weight‑loss medication Wegovy to more than 1 million people with cardiovascular disease to help prevent deadly heart attacks and strokes. Clinical trials show that semaglutide, the How weight-loss wonder drugs are

For guidance on the broader landscape of peptides used in metabolic and hormonal health, see Peptides for Insulin Resistance: GLP-1, Tesamorelin & Emerging Compounds

Lee S, Lee SM, Lee SH, Choi W-K, Park S-J, Kim DY

Food and Drug Administration approval of semaglutide (Ozempic) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), its impact on clinical practice is becoming increasingly evident

But while the side effects are few, they do exist

That medication is Retatrutide , a triple hormone receptor agonist currently in late-stage clinical trials, demonstrating unprecedented effects on body weight, blood glucose, liver fat, and insulin sensitivity